Last updated: July 3, 2026
Cosmo Technologies Limited v. Lupin Ltd. 1:15-cv-00669-LPS: Litigation Summary, Claims at Stake, and Generic-Entry Risk
Cosmo Technologies Limited v. Lupin Ltd., case 1:15-cv-00669-LPS (D. Delaware) is a generic patent challenge and infringement case tied to a Cosmo small-molecule drug product and Lupin’s FDA-directed generic development. The dispute centers on Orange Book-listed patents and the legal availability of market-entry designarions (including potential Paragraph IV positions), with the litigation posture driving whether and when Lupin can launch against Cosmo’s exclusivity and patent estate.
What is Cosmo Technologies Limited v. Lupin Ltd. 1:15-cv-00669-LPS about?
Answer: The case is a Delaware Hatch-Waxman patent litigation between Cosmo (plaintiff) and Lupin (defendant) concerning infringement of listed patents covering a Cosmo product and an asserted right to exclude generic entry.
Core parties and court
- Plaintiff: Cosmo Technologies Limited
- Defendant: Lupin Ltd.
- Court: United States District Court for the District of Delaware
- Case No.: 1:15-cv-00669-LPS
- Judge: L. P. Stark (LPS) (per case caption style)
Procedural posture that typically governs outcomes in this docket
In Hatch-Waxman patent disputes, outcomes are driven by:
- which patents are asserted (often composition, formulation, method-of-use, and/or manufacturing),
- how the defendant responds (non-infringement, invalidity, unenforceability),
- any teaching-by-design workarounds that the generic can implement to avoid infringement, and
- any settlement-driven license or launch-date commitment.
What patents are asserted in Cosmo v. Lupin 1:15-cv-00669-LPS?
Answer: The complaint and infringement contentions define the asserted patent numbers, asserted claims, and the Orange Book tie to the relevant NDA/ANDA.
Why asserted-patent identification matters
- If the asserted set is heavily formulation/manufacturing, Lupin’s freedom-to-operate hinges on process and excipient choices.
- If the asserted set includes method-of-use, Lupin’s risk can persist even with a “label-design” that avoids the infringement claim elements.
- If the asserted set includes therapeutic composition, a workaround may require new dosage forms or different polymorph/solid-state strategy.
Citation status
This response cannot include the specific asserted patent numbers, claim numbers, or Orange Book links because the underlying docket text (complaint, amended complaint, infringement contentions, claim charts, and court orders) is not present in the provided material.
How does the court evaluate infringement and invalidity in Hatch-Waxman cases like this?
Answer: Delaware applies Federal Circuit standards for claim construction and invalidity while handling the litigation under the Hatch-Waxman framework.
Key analytic levers that affect outcomes
- Claim construction: terms tied to solid-state form, dissolution profile, particle size, coating parameters, or formulation components often control infringement.
- Validity:
- anticipation/obviousness based on prior art disclosures,
- written description and enablement for formulation/process claims,
- obviousness where process parameters and ranges are in the prior art.
- Indefiniteness/enforceability: particularly relevant for formulation parameter claims and dependent claim structure.
When does a generic entry become legally blocked in Cosmo v. Lupin-type disputes?
Answer: Entry timing is blocked until a final court judgment or a settlement terms trigger the ability to launch.
In practice, blockers fall into two buckets
- Patent-barrier blockers
- If asserted patents are not found invalid or not infringed, launch is delayed.
- Exclusivity + settlement blockers
- Even if some patents fall, other still-effective patents can keep the generic from launching.
Designated launch timing drivers
- district court trial outcome and permanent injunction scope, and/or
- any negotiated settlement that sets a date (often tied to dismissal without prejudice of certain claims, covenant not to sue, or a license schedule).
What is the likely generic launch scenario for Lupin if Cosmo wins or loses?
Answer: If Cosmo wins on at least one asserted, enforceable patent, Lupin’s launch is usually blocked. If Lupin invalidates or non-infringes the asserted patents that control entry, Lupin can move toward launch subject to:
- remaining unlitigated Orange Book patents,
- regulatory readiness (ANDA approval and labeling),
- any appellate stay or superseding injunction terms.
Stays and appeals
- If a win for Cosmo occurs, generic launches typically remain stayed pending appeal depending on injunction scope and bonding posture.
- If a win for Lupin occurs, the next gating item is whether an injunction is denied and whether any remaining patents still bar entry.
What Paragraph IV litigation risks does Lupin face in Cosmo v. Lupin 1:15-cv-00669-LPS?
Answer: Paragraph IV disputes present two main risks: liability exposure for infringement and pre-launch forfeiture if the court finds the generic’s challenge incorrect.
Risk profile
- Infringement risk: driven by claim construction and mapping of accused product/label and manufacturing parameters.
- Invalidity risk: driven by prior art scope and whether the asserted claims are obvious or anticipated.
- Incentive misalignment: if the generic challenge is narrow but the patent estate is broad, Lupin can lose even with partial invalidity findings.
Is there a settlement agreement affecting entry in Cosmo v. Lupin 1:15-cv-00669-LPS?
Answer: Settlement terms, if any, are reflected in docket entries such as joint stipulations of dismissal, consent judgments, or agreed covenants not to sue. This response cannot confirm settlement existence or terms because the docket record text and orders are not provided.
What FDA pathway and Orange Book linkage matters most for this case?
Answer: Hatch-Waxman patent litigation is tethered to:
- the approved NDA reference,
- the ANDA submitted by Lupin,
- the Orange Book patents listed for the referenced product,
- and the filing’s certification status (Paragraph IV or other).
Why the Orange Book listing drives the case
- Only Orange Book-listed patents typically get asserted in a Hatch-Waxman infringement action under the 35 U.S.C. § 271(e)(2) construct.
- The patent listed as controlling for a given certification can define the litigation’s practical exit ramp.
How strong is Cosmo’s patent estate versus Lupin’s generic position?
Answer: The strength assessment depends on the specific asserted claims, their construction, and the prior art record developed in the docket. This response cannot rate claim strength without:
- patent numbers,
- asserted claim mapping,
- claim construction rulings,
- validity findings or standards applied in the orders.
What claim types are most often decisive in Cosmo small-molecule generics fights?
Answer: In Cosmo-related generic disputes, outcomes often hinge on one or more of:
- formulation parameter claims (composition and performance parameters),
- solid-state/polymorph claims (where applicable),
- method-of-use claims tied to a dosing regimen,
- manufacturing/process claims that constrain how the generic makes the product.
How that impacts design-arounds
- If the claims are formulation-performance driven, design-arounds often require new excipient systems or revised manufacturing controls that reproduce or avoid specific release/dissolution behavior.
- If the claims are method-of-use driven, design-arounds may require label changes or a narrow at-risk patient population.
How does this litigation compare with other Cosmo vs. generic company disputes?
Answer: Comparisons in this fact pattern are generally made by:
- number and types of asserted patents,
- whether the case reached claim construction summary judgment,
- trial outcomes,
- and whether a license/settlement created staggered entry.
This response cannot perform a grounded comparison without the key factual outcomes and patent lists from this specific docket and corresponding competitor matters.
Case impact: What does Cosmo v. Lupin mean for investors, licensing, and R&D?
Answer: The commercial impact is the expected effect on generic launch probability and timing, which then affects:
- Cosmo’s near-to-mid-term revenue protection,
- Lupin’s competitive positioning in the generic portfolio,
- and the cost of alternative development paths (line extensions, new dosage forms, or new formulations).
Practical business read-through
- If the litigation resulted in an injunction or post-judgment stay, Lupin’s value shifts to future patent-expiration windows.
- If Lupin prevailed or settled with earlier-than-default entry, the competitive threat moves from “long dated” to “time-boxed.”
Key Takeaways
- Cosmo Technologies Limited v. Lupin Ltd., 1:15-cv-00669-LPS is a Delaware Hatch-Waxman-style patent infringement dispute tied to Orange Book patents and an FDA-facing generic entry plan.
- The decision and any settlement determine whether Lupin can launch and on what timeline.
- A complete, claim-specific analysis of asserted patents, claim types, court rulings, and entry timing requires docket orders and the complaint/infringement contention record, which are not included in the provided input.
FAQs
- What is the difference between a Paragraph IV certification and a non-Paragraph IV certification in Hatch-Waxman litigation?
- How do claim construction outcomes typically influence infringement findings in formulation patent disputes?
- When does an appeal stay affect a generic’s ability to launch after a district court decision?
- What settlement structures are common in Cosmo-style Hatch-Waxman cases (license, covenant not to sue, entry-date agreement)?
- How do method-of-use claims affect generic label design and risk of off-label infringement?
References
- U.S. District Court for the District of Delaware, case docket 1:15-cv-00669-LPS (Cosmo Technologies Limited v. Lupin Ltd.).
